Search results
Results from the WOW.Com Content Network
Phase 1 (72): single-center, dose-escalation, first in human study in 2 age groups: 18-55 years-old and 56-75 years-old. Phase 2: Multi-center, observer-blinded, placebo-controlled study to assess the safety, reactogenicity, and immunogenicity in healthy adults between 18-75 years old. May-September 2021, Thailand: Preclinical: COVID‑19/aAPC ...
A further study conducted by the US Centers for Disease Control and Prevention (CDC) between December 2020, and March 2021, on nearly 4 thousand health care personnel, first responders, and other essential and frontline workers concluded that under real-world conditions, mRNA vaccine effectiveness of full immunization (14 days or more after ...
In the UK, 15,121 health care workers from 104 hospitals who had tested negative for antibodies prior to the study, were followed by RT-PCR tests twice a week from 7 December 2020 to 5 February 2021, a study compared the positive results for the 90.7% vaccinated share of their cohort with the 9.3% unvaccinated share, and found that the Pfizer ...
This template is used to provide data for COVID-19 vaccine, COVID-19 pandemic by country and territory, and Deployment of COVID-19 vaccines. References [ edit ]
The XEC variant has become the second-most prevalent strain in the country, representing more than 1 in 10 cases, according to data from the Centers for Disease Control and Prevention (CDC). (It ...
Vaccine Initial effectiveness by severity of COVID-19 Study location Refs Asymptomatic Symptomatic Hospitalization Death Oxford–AstraZeneca
The Vaccine Research Center (VRC), is an intramural division of the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), US Department of Health and Human Services (HHS). The mission of the VRC is to discover and develop both vaccines and antibody-based products that target infectious ...
Pan-coronavirus vaccine candidates include variant-proof vaccines such as SpFN, developed by the US Army. It uses a ferritin nanoparticle with prefusion-stabilized spike antigens from the Wuhan strain. Another candidate is RBD–scNP, which is a sortase A-conjugated ferritin nanoparticle with receptor-binding domain (RBD) antigens.